Trials 24
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03682094 | Aug 2018 → Jan 2020 | — | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT00971711 | Sep 2009 → Dec 2013 | irritable bowel syndrome | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT00099723 | Oct 2004 → Dec 2005 | fatty liver disease | VSL Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03511365 | May → Dec 2018 | NAFLD1 | Northwell Health | Terminated | No outcome recorded |
| Phase 1/2 | NCT01032941 | Dec 2009 → Jun 2011 | portal hypertension | University of Alberta | Completed | No outcome recorded |
| Phase 26 trials · 1 missed | ||||||
| Phase 2 | NCT05608928 | Dec 2022 → May 2023 | — | Tropical Gastroenterology & Nutrition Group (TROPGAN) | Unknown | No outcome recorded |
| Phase 2 | NCT03165747 | Oct 2017 → Mar 2019 | postmenopausal osteoporosis | Emory University | Terminated | No outcome recorded |
| Phase 2 | NCT01701297 | Feb 2012 → Oct 2014 | cirrhosis of liver | Nottingham University Hospitals NHS Trust | Terminated | No outcome recorded |
| Phase 2 | NCT01465802 | Dec 2011 → May 2015 | non-small cell lung carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00630838 | Sep 2006 → Sep 2010 | Hirschsprung disease | University of Michigan | Completed | Missed primary |
| Phase 2 | NCT00319007 | Apr → Dec 2006 | classic or attenuated familial adenomatous polyposis | Radboud University Medical Center | Unknown | No outcome recorded |
| Phase 2/33 trials · 1 missed | ||||||
| Phase 2/3 | NCT03078530 | Sep 2013 → May 2018 | persian gulf syndrome | Ashok Tuteja | Unknown | No outcome recorded |
| Phase 2/3 | NCT01110447 | Apr 2010 → Mar 2013 | hepatic encephalopathy | CD Pharma India Pvt. Ltd. | Completed | Missed primary |
| Phase 2/3 | NCT01008293 | Oct 2009 → Jun 2012 | hepatic encephalopathy, liver disorder | CD Pharma India Pvt. Ltd. | Completed | No outcome recorded |
| Phase 33 trials · 1 missed | ||||||
| Phase 3 | NCT02545413 | May 2016 → Jun 2017 | irritable bowel syndrome | Next Gen Pharma India Pvt. Ltd. | Withdrawn | No outcome recorded |
| Phase 3 | NCT00175292 | Dec 2003 → ? | Crohn disease | University of Alberta | Completed | Missed primary |
| Phase 3 | NCT01134692 | — | cirrhosis of liver, esophageal varices | Govind Ballabh Pant Hospital | Unknown | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT01638208 | Aug → Dec 2012 | irritable bowel syndrome | Asian Institute of Gastroenterology, India | Unknown | No outcome recorded |
| Phase 4 | NCT01479660 | Mar 2011 → Oct 2014 | ulcerative colitis | Post Graduate Institute of Medical Education and Research, Chandigarh | Unknown | No outcome recorded |
| Phase 4 | NCT00418340 | Dec 2007 → ? | irritable bowel syndrome | London North West Healthcare NHS Trust | Unknown | No outcome recorded |
| Phase 4 | NCT00114465 | Jun 2005 → Dec 2008 | Crohn disease | Orphan Australia | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT05007470 | Jan 2022 → Jun 2025 overdue | alcoholic liver disease | University of California, Los Angeles | Active not recruiting | No outcome recorded |
| — | NCT01196481 | Dec 2012 → Aug 2015 | cirrhosis of liver | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
| — | NCT00179582 | Jan 2005 → Jan 2006 | irritable bowel syndrome | Beth Israel Deaconess Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Comparator or background therapy8 trials | ||||||
| Phase 0 | NCT01635192 Comparator | Dec 2011 → Jul 2013 | — | Göteborg University | Completed | No outcome recorded |
| Phase 1 | NCT00932841 Comparator | Jan 2008 → Aug 2011 | irritable bowel syndrome | Dayton Children's Hospital | Terminated | No outcome recorded |
| Phase 1/2 | NCT00852124 Comparator | Feb 2007 → Jan 2013 | asthma | University of Maryland, Baltimore | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT02011542 Comparator | Sep 2013 → Jul 2016 | persian gulf syndrome | University of Utah | Terminated | No outcome recorded |
| Phase 2/3 | NCT00973908 Comparator | Apr 2010 → Apr 2012 | diarrheal disease | National Health Service, United Kingdom | Completed | No outcome recorded |
| Phase 2/3 | NCT00678613 Comparator | Jul 2007 → ? | cirrhosis of liver, infectious peritonitis | All India Institute of Medical Sciences | Unknown | No outcome recorded |
| Phase 4 | NCT01632462 Comparator | Sep 2012 → Dec 2014 | Crohn disease | Federico II University | Unknown | No outcome recorded |
| Phase 4 | NCT01178372 Comparator | Sep 2008 → Sep 2010 | hepatic encephalopathy | Govind Ballabh Pant Hospital | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-12-17 | Exegi Pharma, LLC | Results ExeGi Pharma Positive Topline Results in EXE-346 PROF Phase 1b Study exegipharma.com ↗
ExeGi Pharma LLC, a company focused on developing live biotherapeutic (“LBP”) drugs and probiotics, announced positive topline results in the Phase 1b portion of its PROF study. |
| 2017-05-04 | Exegi Pharma, LLC | Results Visbiome Probiotic May Play a Role in Recovery of GI Functions in HIV Patients exegipharma.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-12-17 | Exegi Pharma, LLC | ExeGi Pharma Positive Topline Results in EXE-346 PROF Phase 1b Study exegipharma.com ↗ |
| 2017-05-04 | Exegi Pharma, LLC | Visbiome Probiotic May Play a Role in Recovery of GI Functions in HIV Patients exegipharma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 32 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VSL#3 | “VSL#3 is a commercial probiotic mixture consisting of eight probiotic lactic acid bacteria and Bifidobacteria including Lactobacillus acidophilus, Lactobacillus plantarum,...” NCT05608928 ↗35“The probiotic VSL #3 is easily available, cheap, effective and safe alternative or substitute for the existing therapeutic agents will be evaluated in this study for their...” NCT01479660 ↗ “This will be a double blind randomized placebo controlled study to determine the clinical efficacy of 12 weeks of oral probiotics (VSL#3) in patients with inflammatory bowel disease.” NCT01479660 ↗ “Patients will be randomised to receive either VSL#3 (450 billion lyophilized bacteria/sachet) twice daily for 4 weeks or a placebo powder containing starch but no bacteria.” NCT00418340 ↗ “The probiotic product VSL#3® comes in a powder (sachet) that is to be dissolved in half a glass of cold water before ingestion.” NCT01635192 ↗ “Patients will receive one VSL #3 sachets twice a day for the duration of the antibiotic course and for one week after.” NCT00973908 ↗ “Adults with IBS were randomized into an open label trial to receive the probiotic VSL#3 for 4 or 8 weeks.” PMID 35295488 ↗ Sep 2021 “Patients in this group will be given the probiotic VSL#3 2 packets BID for a total of 8 weeks.” NCT01032941 ↗ “VSL#3 probiotic 4 capsules orally daily or 1 sachet orally daily for up to 5 weeks” NCT01465802 ↗ “VSL#3 is a commercial probiotic mixture consisting of eight bacterial strains:” NCT05007470 ↗ “VSL #3 (probiotic mixture) is given to this group” NCT02011542 ↗ |
| Modality | Other / unclassified | “Probiotics, living bacteria taken orally” NCT00099723 ↗ |
| Route | Oral | “Probiotics, living bacteria taken orally” NCT00099723 ↗ |